Navigation Links
FDA Announces Safety Risk Associated with HIV Drug
Date:2/1/2010

Rare, but serious, liver disorder reported in some patients

SILVER SPRING, Md., Feb. 1 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that non-cirrhotic portal hypertension, a rare, but serious, liver disorder, has been reported in some HIV patients taking Videx/Videx EC (didanosine).

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO )

Videx is an antiretroviral medicine first approved by the FDA in 1991. Videx EC is a delayed-release version of Videx approved in 2000. Videx/Videx EC is used in combination with other antiretroviral medicines to treat HIV infection in children and adults.

During an 18-year period, 42 cases of non-cirrhotic portal hypertension were reported to the FDA's Adverse Event Reporting System for patients taking Videx/Videx EC. Four patients died from bleeding or liver failure after developing the condition.

Non-cirrhotic portal hypertension occurs when blood flow in the portal vein -- a major vein in the liver -- slows down and leads to severely enlarged veins in the esophagus. These enlarged veins, called esophageal varices, are thin and can break open, resulting in serious, and potentially fatal, bleeding.

The Videx and Videx EC product labels have been revised to help ensure that health care professionals and patients are aware of the risk and the signs and symptoms of non-cirrhotic portal hypertension.

The FDA evaluation concluded that the clinical benefits of Videx/Videx EC in certain patients with HIV continue to outweigh potential safety risks. Videx/Videx EC does not cure HIV infection, may not prevent development of HIV-related illnesses, and may not prevent the spread of HIV to other people.  

Videx/Videx EC is marketed by Princeton, N.J.-based Bristol-Myers Squibb.

For more information:

FDA Drug Safety Communication: Serious liver disorder associated with the use of Videx/Videx EC (didanosine)

http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm199169.htm  

Media Inquiries: Erica Jefferson, 301-796-4988; erica.jefferson@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

RELATED LINKS
http://www.fda.gov/

'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Recondo Technology Announces Omni278 UnitedHealthcare Admission Notification Service
2. Trek Bicycle Announces Title Sponsorship of 2010 Dirt Series
3. Sinovac Announces Exercise of Over-Allotment Option
4. Rapport International Announces Partnership with SDL
5. DBLG Announces Release 1.0 of the HITECH Act Survival Guide: an Open Source Law Initiative
6. Southwest Airlines Announces Recipients of its 2010 Medical Transportation Grant Program
7. Dr. David Williams Announces Launch of New Online Digestion Clinic
8. Code Hennessy & Simmons LLC Announces Sale of Suture Express, Inc.
9. Care Investment Trust Inc. Announces Stockholder Approval of Plan of Liquidation
10. PDL BioPharma Announces Two $0.50 Dividends in 2010
11. AMD Alliance International Announces $10,000 Video Contest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... 2017 , ... Every year, thousands of dedicated Higher Education and K12 professionals ... is coupled with a dynamic theme like Camp Canvas; this year, they’ve managed to ... , To extend their partnership with Canvas beyond the LMS integration, Modo Labs ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... organizations that already work hand-in-hand on an Innovation Collaboration program, have signed a ... quality, experience and cost of the care members and patients receive. The agreement ...
(Date:7/24/2017)... ... ... Anyone who uses scales know they have limits; a small kitchen scale ... scale to dispense medication. The first example is an issue of capacity, while the ... important to have the right balance for the process. METTLER TOLEDO’s new white paper, ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... solution focused on delivering end-to-end sleep health care at scale, indicates record-breaking ... shows that adherence rates for positive airway pressure (PAP) therapy, the most widely ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... received the prestigious StorErotica “Consumer’s Choice” Award, for favorite sex toy. Created in ... 11th annual StorErotica Awards to be consumer voted. The Magic Wand Rechargeable won ...
Breaking Medicine News(10 mins):
(Date:7/6/2017)... 2017 ThriveRx, the nutrition division of Diplomat Specialty Infusion Group, ... on nutrition support. To celebrate its anniversary, ThriveRx recently launched ... fresh new look with improved organization to create the best user experience ... ... "We,ve made several great ...
(Date:7/5/2017)... 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... received approval from the Israel Securities Authority to dual-list its ... common stock will commence trading on the TASE on July ... market capitalization of the Company, it is expected that Oramed ...
(Date:7/5/2017)... July 5, 2017   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade cell and tissue ... media ("BioLife"), today announced that it has reached an ... and largest shareholder, to modify its existing credit facility ... the modification, WAVI agreed to exchange its existing $4.25 ...
Breaking Medicine Technology: